Abstract 13600: Evaluation of the Risk of All-Cause Mortality With and Without Antithrombotic Therapy in Patients with Newly Diagnosed Atrial Fibrillation and Low-to-Moderate Stroke Risk
Abstract
Background: Evidence regarding the impact of antithrombotic therapy on mortality in atrial fibrillation (AF) patients with low-to-moderate stroke risk remains uncertain. We evaluated the risk of all-cause mortality in low-to-moderate stroke risk AF patient categories and examine the association of event rates with antithrombotic treatment. Methods: Using UK linked administrative databases, we enrolled all newly diagnosed AF individuals aged ≥18 years, with information on antithrombotic therapy prescription at time of diagnosis and on continuous medication throughout study duration. All-cause mortality was calculated in subgroups receiving either no antithrombotic therapy, antiplatelets or oral anticoagulants (OACs) within low and moderate stroke risk categories using CHADS 2 and CHA 2 DS 2 VASc/CHA 2 DS 2 VA. Results: We included 196,779 patients (age 75.8±12.3 years, 49.1% females, 97.6% white). Of them, 120,605 (61.3%) received no antithrombotic, 33,957 antiplatelet (17.2%) and 42,217 OAC treatment (21.5%). After adjusting for age, gender and co-morbidities, over a median follow-up of 5.9 years (IQR 2.5-10.5), patients receiving OACs showed significant reduction of all-cause mortality in low and moderate risk categories (CHADS 2 3.16 vs. 3.66 per 100 patient-years, HR 0.69, 95%CI 0.65-0.74, and 5.49 vs. 11.41 per 100 patient-years, HR 0.58, 95%CI 0.56-0.60; CHA 2 DS 2 VASc/CHA 2 DS 2 VA 1.78 vs 1.95, HR 0.80, 95%CI 0.71-0.90, and 3.36 vs 5.02; HR 0.65, 95%CI 0.61-0.69, respectively) (Figure). Treatment with OACs was not associated with a significant reduction in stroke incidence across any risk categories of the investigated risk stratification instruments. Conclusions: In newly diagnosed AF patients with low-to-moderate stroke risk, immediate and continuous treatment with OACs was associated with significant reduction in all-cause mortality.